Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 102 entries
Sorted by: Best Match Show Resources per page
Comparison of Biological Screening and Diagnostic Indicators to Detect In Utero Opiate and Cocaine Exposure Among Mother-Infant Dyads: Erratum.

Therapeutic drug monitoring

[No authors listed]
PMID: 29529011
Ther Drug Monit. 2018 Apr;40(2):284. doi: 10.1097/FTD.0000000000000481.

No abstract available.

Cite
Comparison of Biological Screening and Diagnostic Indicators to Detect In Utero Opiate and Cocaine Exposure Among Mother-Infant Dyads: Erratum. Ther Drug Monit. 2018;40(2):284doi: 10.1097/FTD.0000000000000481.
(2018). Comparison of Biological Screening and Diagnostic Indicators to Detect In Utero Opiate and Cocaine Exposure Among Mother-Infant Dyads: Erratum. Therapeutic drug monitoring, 40(2), 284. https://doi.org/10.1097/FTD.0000000000000481
"Comparison of Biological Screening and Diagnostic Indicators to Detect In Utero Opiate and Cocaine Exposure Among Mother-Infant Dyads: Erratum." Therapeutic drug monitoring vol. 40,2 (2018): 284. doi: https://doi.org/10.1097/FTD.0000000000000481
Comparison of Biological Screening and Diagnostic Indicators to Detect In Utero Opiate and Cocaine Exposure Among Mother-Infant Dyads: Erratum. Ther Drug Monit. 2018 Apr;40(2):284. doi: 10.1097/FTD.0000000000000481. PMID: 29529011.
Copy Download .nbib Format: NLM
Therapeutic Drug Monitoring of Busulfan for the Management of Pediatric Patients: Cross-Validation of Methods and Long-Term Performance: Erratum.

Therapeutic drug monitoring

[No authors listed]
PMID: 29529013
Ther Drug Monit. 2018 Apr;40(2):284. doi: 10.1097/FTD.0000000000000489.

No abstract available.

Cite
Therapeutic Drug Monitoring of Busulfan for the Management of Pediatric Patients: Cross-Validation of Methods and Long-Term Performance: Erratum. Ther Drug Monit. 2018;40(2):284doi: 10.1097/FTD.0000000000000489.
(2018). Therapeutic Drug Monitoring of Busulfan for the Management of Pediatric Patients: Cross-Validation of Methods and Long-Term Performance: Erratum. Therapeutic drug monitoring, 40(2), 284. https://doi.org/10.1097/FTD.0000000000000489
"Therapeutic Drug Monitoring of Busulfan for the Management of Pediatric Patients: Cross-Validation of Methods and Long-Term Performance: Erratum." Therapeutic drug monitoring vol. 40,2 (2018): 284. doi: https://doi.org/10.1097/FTD.0000000000000489
Therapeutic Drug Monitoring of Busulfan for the Management of Pediatric Patients: Cross-Validation of Methods and Long-Term Performance: Erratum. Ther Drug Monit. 2018 Apr;40(2):284. doi: 10.1097/FTD.0000000000000489. PMID: 29529013.
Copy Download .nbib Format: NLM
Optimal Practice for Vancomycin Therapeutic Drug Monitoring: Position Statement From the Anti-infectives Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.

Therapeutic drug monitoring

Reuter SE, Stocker SL, Alffenaar JC, Baldelli S, Cattaneo D, Jones G, Koch BCP, Kocic D, Mathew SK, Molinaro M, Neely M, Sandaradura I, Marriott DJE.
PMID: 34882107
Ther Drug Monit. 2022 Feb 01;44(1):121-132. doi: 10.1097/FTD.0000000000000944.

ABSTRACT: Individualization of vancomycin dosing based on therapeutic drug monitoring (TDM) data is known to improve patient outcomes compared with fixed or empirical dosing strategies. There is increasing evidence to support area-under-the-curve (AUC24)-guided TDM to inform vancomycin dosing decisions...

Cite
Reuter SE, Stocker SL, Alffenaar JC, et al. Optimal Practice for Vancomycin Therapeutic Drug Monitoring: Position Statement From the Anti-infectives Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit. 2022;44(1):121-132doi: 10.1097/FTD.0000000000000944.
Reuter, S. E., Stocker, S. L., Alffenaar, J. C., Baldelli, S., Cattaneo, D., Jones, G., Koch, B. C. P., Kocic, D., Mathew, S. K., Molinaro, M., Neely, M., Sandaradura, I., & Marriott, D. J. E. (2022). Optimal Practice for Vancomycin Therapeutic Drug Monitoring: Position Statement From the Anti-infectives Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic drug monitoring, 44(1), 121-132. https://doi.org/10.1097/FTD.0000000000000944
Reuter, Stephanie E, et al. "Optimal Practice for Vancomycin Therapeutic Drug Monitoring: Position Statement From the Anti-infectives Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology." Therapeutic drug monitoring vol. 44,1 (2022): 121-132. doi: https://doi.org/10.1097/FTD.0000000000000944
Reuter SE, Stocker SL, Alffenaar JC, Baldelli S, Cattaneo D, Jones G, Koch BCP, Kocic D, Mathew SK, Molinaro M, Neely M, Sandaradura I, Marriott DJE. Optimal Practice for Vancomycin Therapeutic Drug Monitoring: Position Statement From the Anti-infectives Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit. 2022 Feb 01;44(1):121-132. doi: 10.1097/FTD.0000000000000944. PMID: 34882107.
Copy Download .nbib Format: NLM
Therapeutic Drug Monitoring of Antibiotic Drugs: The Role of the Clinical Laboratory.

Therapeutic drug monitoring

Shipkova M, Jamoussi H.
PMID: 34726200
Ther Drug Monit. 2022 Feb 01;44(1):32-49. doi: 10.1097/FTD.0000000000000934.

BACKGROUND: Therapeutic drug monitoring (TDM) of anti-infective drugs is an increasingly complex field, given that in addition to the patient and drug as 2 usual determinants, its success is driven by the pathogen. Pharmacodynamics is related both to the...

Cite
Shipkova M, Jamoussi H. Therapeutic Drug Monitoring of Antibiotic Drugs: The Role of the Clinical Laboratory. Ther Drug Monit. 2022;44(1):32-49doi: 10.1097/FTD.0000000000000934.
Shipkova, M., & Jamoussi, H. (2022). Therapeutic Drug Monitoring of Antibiotic Drugs: The Role of the Clinical Laboratory. Therapeutic drug monitoring, 44(1), 32-49. https://doi.org/10.1097/FTD.0000000000000934
Shipkova, Maria, and Jamoussi, Hedi. "Therapeutic Drug Monitoring of Antibiotic Drugs: The Role of the Clinical Laboratory." Therapeutic drug monitoring vol. 44,1 (2022): 32-49. doi: https://doi.org/10.1097/FTD.0000000000000934
Shipkova M, Jamoussi H. Therapeutic Drug Monitoring of Antibiotic Drugs: The Role of the Clinical Laboratory. Ther Drug Monit. 2022 Feb 01;44(1):32-49. doi: 10.1097/FTD.0000000000000934. PMID: 34726200.
Copy Download .nbib Format: NLM
Health Care Costs of Target Attainment for Beta-Lactam Antibiotics in Critically Ill Patients: A Retrospective Analysis of the EXPAT Study.

Therapeutic drug monitoring

Ewoldt TMJ, Abdulla A, Hunfeld NGM, Muller AE, Gommers D, Polinder S, Koch BCP, Endeman H.
PMID: 33770020
Ther Drug Monit. 2022 Feb 01;44(1):224-229. doi: 10.1097/FTD.0000000000000891.

BACKGROUND: Optimizing beta-lactam antibiotic treatment is a promising method to reduce the length of intensive care unit (ICU) stay and therefore reduce ICU costs. We used data from the EXPAT trial to determine whether beta-lactam antibiotic target attainment is...

Cite
Ewoldt TMJ, Abdulla A, Hunfeld NGM, et al. Health Care Costs of Target Attainment for Beta-Lactam Antibiotics in Critically Ill Patients: A Retrospective Analysis of the EXPAT Study. Ther Drug Monit. 2022;44(1):224-229doi: 10.1097/FTD.0000000000000891.
Ewoldt, T. M. J., Abdulla, A., Hunfeld, N. G. M., Muller, A. E., Gommers, D., Polinder, S., Koch, B. C. P., & Endeman, H. (2022). Health Care Costs of Target Attainment for Beta-Lactam Antibiotics in Critically Ill Patients: A Retrospective Analysis of the EXPAT Study. Therapeutic drug monitoring, 44(1), 224-229. https://doi.org/10.1097/FTD.0000000000000891
Ewoldt, Tim M J, et al. "Health Care Costs of Target Attainment for Beta-Lactam Antibiotics in Critically Ill Patients: A Retrospective Analysis of the EXPAT Study." Therapeutic drug monitoring vol. 44,1 (2022): 224-229. doi: https://doi.org/10.1097/FTD.0000000000000891
Ewoldt TMJ, Abdulla A, Hunfeld NGM, Muller AE, Gommers D, Polinder S, Koch BCP, Endeman H. Health Care Costs of Target Attainment for Beta-Lactam Antibiotics in Critically Ill Patients: A Retrospective Analysis of the EXPAT Study. Ther Drug Monit. 2022 Feb 01;44(1):224-229. doi: 10.1097/FTD.0000000000000891. PMID: 33770020; PMCID: PMC8746885.
Copy Download .nbib Format: NLM
Plasma Concentration After the First Hemoperfusion has a High Predictive Value in Medium Level Acute Paraquat-Poisoned Patients.

Therapeutic drug monitoring

Tang Y, Chen H, Qiu W, Zhou Y, Hong G, Hu L, Zhao G, Chen X, Zhi S, Lu Z.
PMID: 34780392
Ther Drug Monit. 2021 Dec 01;43(6):797-806. doi: 10.1097/FTD.0000000000000889.

BACKGROUND: Paraquat ( PQ) is very poisonous to humans and animals and there is no effective clinical antidote . The efficacy of hemoperfusion (HP) treatment for PQ poisoning remains controversial. To explore new ways to predict the prognosis of...

Cite
Tang Y, Chen H, Qiu W, et al. Plasma Concentration After the First Hemoperfusion has a High Predictive Value in Medium Level Acute Paraquat-Poisoned Patients. Ther Drug Monit. 2021;43(6):797-806doi: 10.1097/FTD.0000000000000889.
Tang, Y., Chen, H., Qiu, W., Zhou, Y., Hong, G., Hu, L., Zhao, G., Chen, X., Zhi, S., & Lu, Z. (2021). Plasma Concentration After the First Hemoperfusion has a High Predictive Value in Medium Level Acute Paraquat-Poisoned Patients. Therapeutic drug monitoring, 43(6), 797-806. https://doi.org/10.1097/FTD.0000000000000889
Tang, Yahui, et al. "Plasma Concentration After the First Hemoperfusion has a High Predictive Value in Medium Level Acute Paraquat-Poisoned Patients." Therapeutic drug monitoring vol. 43,6 (2021): 797-806. doi: https://doi.org/10.1097/FTD.0000000000000889
Tang Y, Chen H, Qiu W, Zhou Y, Hong G, Hu L, Zhao G, Chen X, Zhi S, Lu Z. Plasma Concentration After the First Hemoperfusion has a High Predictive Value in Medium Level Acute Paraquat-Poisoned Patients. Ther Drug Monit. 2021 Dec 01;43(6):797-806. doi: 10.1097/FTD.0000000000000889. PMID: 34780392.
Copy Download .nbib Format: NLM
Cerebrospinal Fluid Penetration of Vancomycin During Continuous Infusion Therapy in Patients With Nosocomial Ventriculitis.

Therapeutic drug monitoring

Tuon FF, Yamada CH, Cieslinski J, Dos Santos Oliveira D, Ribeiro VST, Gasparetto J, Telles JP.
PMID: 34780393
Ther Drug Monit. 2021 Dec 01;43(6):807-811. doi: 10.1097/FTD.0000000000000907.

BACKGROUND: This study aimed to evaluate the utility of a commercial kit used to measure serum vancomycin concentrations to determine vancomycin concentrations in cerebrospinal fluid (CSF) samples and evaluate CSF penetration when administered as a continuous high-dose infusion in...

Cite
Tuon FF, Yamada CH, Cieslinski J, et al. Cerebrospinal Fluid Penetration of Vancomycin During Continuous Infusion Therapy in Patients With Nosocomial Ventriculitis. Ther Drug Monit. 2021;43(6):807-811doi: 10.1097/FTD.0000000000000907.
Tuon, F. F., Yamada, C. H., Cieslinski, J., Dos Santos Oliveira, D., Ribeiro, V. S. T., Gasparetto, J., & Telles, J. P. (2021). Cerebrospinal Fluid Penetration of Vancomycin During Continuous Infusion Therapy in Patients With Nosocomial Ventriculitis. Therapeutic drug monitoring, 43(6), 807-811. https://doi.org/10.1097/FTD.0000000000000907
Tuon, Felipe Francisco, et al. "Cerebrospinal Fluid Penetration of Vancomycin During Continuous Infusion Therapy in Patients With Nosocomial Ventriculitis." Therapeutic drug monitoring vol. 43,6 (2021): 807-811. doi: https://doi.org/10.1097/FTD.0000000000000907
Tuon FF, Yamada CH, Cieslinski J, Dos Santos Oliveira D, Ribeiro VST, Gasparetto J, Telles JP. Cerebrospinal Fluid Penetration of Vancomycin During Continuous Infusion Therapy in Patients With Nosocomial Ventriculitis. Ther Drug Monit. 2021 Dec 01;43(6):807-811. doi: 10.1097/FTD.0000000000000907. PMID: 34780393.
Copy Download .nbib Format: NLM
Determination of Guanfacine in Oral Fluid and Serum of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Short Communication.

Therapeutic drug monitoring

Wohkittel C, Scherf-Clavel O, Fekete S, Romanos M, Högger P, Gerlach M.
PMID: 34334681
Ther Drug Monit. 2021 Jul 30; doi: 10.1097/FTD.0000000000000917. Epub 2021 Jul 30.

BACKGROUND: Guanfacine, a selective α2A-adrenoreceptor agonist, is a second-line medication for treating children and adolescents with attention-deficit/hyperkinetic disorder (ADHD). The dosage administered as milligram per body weight to balance the potential benefits and risks of treatment. Therapeutic drug monitoring...

Cite
Wohkittel C, Scherf-Clavel O, Fekete S, et al. Determination of Guanfacine in Oral Fluid and Serum of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Short Communication. Ther Drug Monit. 2021;doi: 10.1097/FTD.0000000000000917.
Wohkittel, C., Scherf-Clavel, O., Fekete, S., Romanos, M., Högger, P., & Gerlach, M. (2021). Determination of Guanfacine in Oral Fluid and Serum of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Short Communication. Therapeutic drug monitoring, . https://doi.org/10.1097/FTD.0000000000000917
Wohkittel, Christopher, et al. "Determination of Guanfacine in Oral Fluid and Serum of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Short Communication." Therapeutic drug monitoring vol. (2021). doi: https://doi.org/10.1097/FTD.0000000000000917
Wohkittel C, Scherf-Clavel O, Fekete S, Romanos M, Högger P, Gerlach M. Determination of Guanfacine in Oral Fluid and Serum of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Short Communication. Ther Drug Monit. 2021 Jul 30; doi: 10.1097/FTD.0000000000000917. Epub 2021 Jul 30. PMID: 34334681.
Copy Download .nbib Format: NLM
Therapeutic Drug Monitoring in the Era of Precision Medicine: Achievements, Gaps, and Perspectives-An Interview in Honor of Professor Charles Pippenger.

Therapeutic drug monitoring

Wong SH, Marquet P, Cattaneo D, Svinarov D, Bergan S, Walson P, Vinks AA, Shipkova M.
PMID: 34654029
Ther Drug Monit. 2021 Dec 01;43(6):719-727. doi: 10.1097/FTD.0000000000000932.

No abstract available.

Cite
Wong SH, Marquet P, Cattaneo D, et al. Therapeutic Drug Monitoring in the Era of Precision Medicine: Achievements, Gaps, and Perspectives-An Interview in Honor of Professor Charles Pippenger. Ther Drug Monit. 2021;43(6):719-727doi: 10.1097/FTD.0000000000000932.
Wong, S. H., Marquet, P., Cattaneo, D., Svinarov, D., Bergan, S., Walson, P., Vinks, A. A., & Shipkova, M. (2021). Therapeutic Drug Monitoring in the Era of Precision Medicine: Achievements, Gaps, and Perspectives-An Interview in Honor of Professor Charles Pippenger. Therapeutic drug monitoring, 43(6), 719-727. https://doi.org/10.1097/FTD.0000000000000932
Wong, Steven H, et al. "Therapeutic Drug Monitoring in the Era of Precision Medicine: Achievements, Gaps, and Perspectives-An Interview in Honor of Professor Charles Pippenger." Therapeutic drug monitoring vol. 43,6 (2021): 719-727. doi: https://doi.org/10.1097/FTD.0000000000000932
Wong SH, Marquet P, Cattaneo D, Svinarov D, Bergan S, Walson P, Vinks AA, Shipkova M. Therapeutic Drug Monitoring in the Era of Precision Medicine: Achievements, Gaps, and Perspectives-An Interview in Honor of Professor Charles Pippenger. Ther Drug Monit. 2021 Dec 01;43(6):719-727. doi: 10.1097/FTD.0000000000000932. PMID: 34654029.
Copy Download .nbib Format: NLM
Determination of Free Valproic Acid Concentration in 569 Clinical Samples by LC-MS/MS After Hollow Fiber Centrifugal Ultrafiltration Treatment.

Therapeutic drug monitoring

Wu X, Li H, Dong W, Yang X, Jin Y, Gong Y, Zhang Z, Liu X.
PMID: 33990504
Ther Drug Monit. 2021 Dec 01;43(6):789-796. doi: 10.1097/FTD.0000000000000903.

OBJECTIVE: To perform therapeutic drug monitoring of total and free plasma valproic acid (VPA) concentrations in clinical samples and to analyze the related factors.METHODS: The total VPA concentration in plasma was determined by ultrahigh-performance liquid chromatography with precolumn derivatization...

Cite
Wu X, Li H, Dong W, et al. Determination of Free Valproic Acid Concentration in 569 Clinical Samples by LC-MS/MS After Hollow Fiber Centrifugal Ultrafiltration Treatment. Ther Drug Monit. 2021;43(6):789-796doi: 10.1097/FTD.0000000000000903.
Wu, X., Li, H., Dong, W., Yang, X., Jin, Y., Gong, Y., Zhang, Z., & Liu, X. (2021). Determination of Free Valproic Acid Concentration in 569 Clinical Samples by LC-MS/MS After Hollow Fiber Centrifugal Ultrafiltration Treatment. Therapeutic drug monitoring, 43(6), 789-796. https://doi.org/10.1097/FTD.0000000000000903
Wu, Xikun, et al. "Determination of Free Valproic Acid Concentration in 569 Clinical Samples by LC-MS/MS After Hollow Fiber Centrifugal Ultrafiltration Treatment." Therapeutic drug monitoring vol. 43,6 (2021): 789-796. doi: https://doi.org/10.1097/FTD.0000000000000903
Wu X, Li H, Dong W, Yang X, Jin Y, Gong Y, Zhang Z, Liu X. Determination of Free Valproic Acid Concentration in 569 Clinical Samples by LC-MS/MS After Hollow Fiber Centrifugal Ultrafiltration Treatment. Ther Drug Monit. 2021 Dec 01;43(6):789-796. doi: 10.1097/FTD.0000000000000903. PMID: 33990504.
Copy Download .nbib Format: NLM
Optimal teicoplanin dosing regimen in neonates and children developed by leveraging real-world clinical information.

Therapeutic drug monitoring

Yamada T, Emoto C, Fukuda T, Motomura Y, Inoue H, Ohga S, Ieiri I.
PMID: 34629445
Ther Drug Monit. 2021 Oct 08; doi: 10.1097/FTD.0000000000000930. Epub 2021 Oct 08.

BACKGROUND: Teicoplanin is a glycopeptide antibiotic used for the treatment of methicillin-resistant Staphylococcus aureus infections. To ensure successful target attainment, therapeutic drug monitoring-informed dosage adjustment is recommended. However, it relies on the experience of the clinician and the frequency...

Cite
Yamada T, Emoto C, Fukuda T, et al. Optimal teicoplanin dosing regimen in neonates and children developed by leveraging real-world clinical information. Ther Drug Monit. 2021;doi: 10.1097/FTD.0000000000000930.
Yamada, T., Emoto, C., Fukuda, T., Motomura, Y., Inoue, H., Ohga, S., & Ieiri, I. (2021). Optimal teicoplanin dosing regimen in neonates and children developed by leveraging real-world clinical information. Therapeutic drug monitoring, . https://doi.org/10.1097/FTD.0000000000000930
Yamada, Takaaki, et al. "Optimal teicoplanin dosing regimen in neonates and children developed by leveraging real-world clinical information." Therapeutic drug monitoring vol. (2021). doi: https://doi.org/10.1097/FTD.0000000000000930
Yamada T, Emoto C, Fukuda T, Motomura Y, Inoue H, Ohga S, Ieiri I. Optimal teicoplanin dosing regimen in neonates and children developed by leveraging real-world clinical information. Ther Drug Monit. 2021 Oct 08; doi: 10.1097/FTD.0000000000000930. Epub 2021 Oct 08. PMID: 34629445.
Copy Download .nbib Format: NLM
Development of a Sensitive and High-throughput Assay for Simultaneous Quantification of Five Tyrosine Kinase Inhibitors and Two Active Metabolites in Human Plasma Using Ultra-high Performance Liquid Chromatography Coupled to Tandem Mass Spectrometry.

Therapeutic drug monitoring

Sumimoto T, Nakahara R, Suzuki Y, Tanaka R, Yoshida N, Ogata M, Itoh H.
PMID: 34469417
Ther Drug Monit. 2021 Aug 27; doi: 10.1097/FTD.0000000000000922. Epub 2021 Aug 27.

BACKGROUND: Breakpoint cluster region-Abelson (BCR-ABL) tyrosine kinase inhibitors (TKIs) demonstrate improved therapeutic efficacy in chronic myeloid leukemia (CML). However, drug-drug interactions, non-adherence, and host-related factors may influence plasma concentrations. Therefore, therapeutic drug monitoring may be necessary for patients presenting...

Cite
Sumimoto T, Nakahara R, Suzuki Y, et al. Development of a Sensitive and High-throughput Assay for Simultaneous Quantification of Five Tyrosine Kinase Inhibitors and Two Active Metabolites in Human Plasma Using Ultra-high Performance Liquid Chromatography Coupled to Tandem Mass Spectrometry. Ther Drug Monit. 2021;doi: 10.1097/FTD.0000000000000922.
Sumimoto, T., Nakahara, R., Suzuki, Y., Tanaka, R., Yoshida, N., Ogata, M., & Itoh, H. (2021). Development of a Sensitive and High-throughput Assay for Simultaneous Quantification of Five Tyrosine Kinase Inhibitors and Two Active Metabolites in Human Plasma Using Ultra-high Performance Liquid Chromatography Coupled to Tandem Mass Spectrometry. Therapeutic drug monitoring, . https://doi.org/10.1097/FTD.0000000000000922
Sumimoto, Takahiro, et al. "Development of a Sensitive and High-throughput Assay for Simultaneous Quantification of Five Tyrosine Kinase Inhibitors and Two Active Metabolites in Human Plasma Using Ultra-high Performance Liquid Chromatography Coupled to Tandem Mass Spectrometry." Therapeutic drug monitoring vol. (2021). doi: https://doi.org/10.1097/FTD.0000000000000922
Sumimoto T, Nakahara R, Suzuki Y, Tanaka R, Yoshida N, Ogata M, Itoh H. Development of a Sensitive and High-throughput Assay for Simultaneous Quantification of Five Tyrosine Kinase Inhibitors and Two Active Metabolites in Human Plasma Using Ultra-high Performance Liquid Chromatography Coupled to Tandem Mass Spectrometry. Ther Drug Monit. 2021 Aug 27; doi: 10.1097/FTD.0000000000000922. Epub 2021 Aug 27. PMID: 34469417.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 102 entries